SecBot SecBot
8-K ·Filed May 28, 2026

PHGE

BiomX Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed5mo ago SEC0001213900-26-061772
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine officer appointment with no stock-moving implications. Monitor for potential transition to full-time employment or changes in engagement level, but no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.56
T+0 close · May 28, 2026 · via day close
Latest settled
−91.19%
T+60 · $0.1375
Vs SPY
−92.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $1.56entry
  2. T+1 · 6mo ago −19.23%α −19.47% · $1.26
  3. T+5 · 6mo ago −44.36%α −44.31% · $0.8680
  4. T+20 · 5mo ago −74.64%α −71.50% · $0.3956
  5. T+60 · 3mo ago −91.19%α −92.92% · $0.1375
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX Inc. appointed Roy Rousso as Chief Business Officer (and, per the consulting agreement, COO/CBO) effective July 1, 2026, via a consulting agreement with $11,900/month base compensation at a 70% engagement level, plus eligibility for an annual performance bonus of up to $71,400 and a 200,000-share equity grant vesting over three years. This is a routine officer appointment with no material financial data or strategic changes disclosed, and no departures were announced.

Key Facts

  • Appointed Roy Rousso as Chief Business Officer effective July 1, 2026
  • Consulting agreement: $11,900/month base fee (70% of full-time $17,000/month)
  • Annual performance bonus up to 50% of base fee (up to $71,400 per annum at 70% engagement)
  • Equity grant of 200,000 shares of common stock, vesting in 3 equal annual installments
  • 12-month post-termination non-compete and non-solicitation covenants
  • Part-time independent contractor arrangement; parties intend to transition to full-time salaried employment as business develops

Financial Impact

Annual cash compensation of approximately $142,800 in base fee plus up to $71,400 bonus potential at current engagement level; 200,000 share equity award with three-year vesting

operating expenses (SG&A)

Risk Factors

  • Part-time engagement may limit bandwidth relative to a full-time COO/CBO
  • Equity grant adds modest shareholder dilution (~200K shares vs $16M market cap)

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-061772
Document: ea0292479-8k_biomx.htm0001213900-26-061772
Document: 0001213900-26-061772-index-headers.html0001213900-26-061772
Document: 0001213900-26-061772-index.html0001213900-26-061772
Document: 0001213900-26-061772.txt0001213900-26-061772

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026